Home › Enanta Pharmaceuticals Announces New Data Presented On Protease Inhibitor ABT-493 At The 21st Conference On Retroviruses And Opportunistic Infections (CROI)
 

Keywords :   


Enanta Pharmaceuticals Announces New Data Presented On Protease Inhibitor ABT-493 At The 21st Conference On Retroviruses And Opportunistic Infections (CROI)

2014-03-05 04:59:35| drugdiscoveryonline Home Page

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, recently announced that new in vitro data on ABT-493, a potent NS3/4 protease inhibitor, was presented today during a poster session at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

Tags: data presented conference 21st

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.11Subtropical Storm Patty Graphics
02.11Atlantic Tropical Weather Outlook
02.11Eastern North Pacific Tropical Weather Outlook
02.11Tropical Storm Lane Graphics
02.11Subtropical Storm Patty Graphics
02.11Tropical Storm Lane Forecast Discussion Number 4
02.11Subtropical Storm Patty Wind Speed Probabilities Number 2
02.11Summary for Tropical Storm Lane (EP3/EP132024)
More »